Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LAT8881 crossover study for acute migraine
ACTRN12619001369112Phase 2Completed
- Sponsor
- Lateral Pharma
- Start
- Oct 2019
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of LAT8881 in migraine with aura and migraine without aura (2 arms), sponsored by Lateral Pharma. Primary endpoint: Change in migraine headache pain score. Started Oct 2019; status: completed.
02
Drugs
LAT8881
03
Conditions
migraine with auramigraine without aura
Beyond the preview
Go deeper on ACTRN12619001369112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619001369112.